Bio-engineered Proteins: Trial Confirms New Way To Tackle Cancer

Re-engineering a protein that helps prevent tumours spreading and growing has created a potentially powerful therapy for people with many different types of cancer. In a study published in the first issue of EMBO Molecular Medicine, Canadian researchers modified the tumour inhibiting protein, von Hippel-Lindau (VHL), and demonstrated that it could suppress tumour growth in mice.


When solid tumours grow they often have relatively poor and disorganised blood supplies. As a result, various regions including the centre of the tumour have low levels of oxygen and are said to be hypoxic. Cells in these hypoxic areas produce hypoxia-inducible factor (HIF) that helps them carry on growing. Consequently HIF is associated with aggressiveness in some of the most common types of cancer, including prostate, breast, colon and lung cancer. Under normal conditions VHL degrades HIF, but VHL is deactivated when oxygen levels are low. So, in hypoxic regions of a tumour, just where VHL is needed to inhibit cancer, it is ineffective.


The researchers, therefore, created a new version of VHL that does not stop working when oxygen is scarce. Introducing this newly engineered version of VHL into mice that had kidney tumours dramatically reduced levels of HIF, caused tumours to regress and limited the formation of new blood vessels within the tumours.



"We have genetically removed the Achilles' heel of VHL to permit unrestricted destruction of HIF," says lead researcher Professor Michael Ohh, who works in the Faculty of Medicine at the University of Toronto. "The level of HIF is usually very high under conditions of low oxygen, but when we put in our bioengineered VHL its levels go right down to a level that would be comparable to that in normal oxygen levels."


Their findings could have implications for any type of cancer in which HIF plays a role. "We used kidney cancer as a model because it is one of the most resistant tumours to conventional radiation and chemotherapy, but our findings provide a novel concept that could potentially serve as a foundation for smarter anti-cancer strategy for a wide variety of cancers," says Ohh.


Full citation:

Oxygen-Independent Degradation Of Hif Via Bioengineered Vhl Tumour Suppressor Complex;

Sufan R.I., Moriyama E.H., Mariampillai A., Roche O., Evans A.J., Alajez N.M., Vitkin I.A., Yang V.X.D., Liu F., Wilson B.C., Ohh M.;

EMBO Mol Med 2009 1(1); DOI: emmm.200900004


About the Journal


Molecular Medicine is a rapidly-growing area of research at the interface between clinical research and basic biology. Powerful new analytical tools provided by molecular biology allow unprecedented insights into human physiology and the molecular basis of diseases. These insights are being translated into better diagnosis, prevention and patient care. EMBO Molecular Medicine is a peer-reviewed journal dedicated to the publication of original, cutting-edge research in the field of Molecular Medicine of interest to medical and basic scientists. The Journal publishes research articles and reviews highly relevant to all fields of clinical medicine and their related research areas in basic biology. Studies based on model organisms also fall within the scope of the journal, provided that the results presented are evidently relevant to human disease.
For more information please visit embomolmed.















Wiley-Blackwell's business model for new journals


EMBO Molecular Medicine will be made freely available for the first two years of publication. Institutional customers can opt to receive complimentary online access for this journal. Institutions may also request one complimentary print subscription when registering for online access to EMBO Molecular Medicine. Register your institution here.



About EMBO


The European Molecular Biology Organization (EMBO) promotes excellence in molecular life sciences by recognizing and fostering talented scientists, empowering them to advance the life sciences to understand how life works and share knowledge to help address the challenges of a changing world. For details about EMBO and its activities please visit embo.


Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit wiley-blackwell or interscience.wiley.


Source
Wiley-Blackwell